Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Acumen Pharmaceuticals, Inc. (ABOS) had Normalized Pre-Tax Income of $-20.74M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-20.74M |
|
-- |
|
-- |
|
$21.15M |
|
$-21.15M |
|
$0.41M |
|
$-20.74M |
|
|
Normalized Pre-Tax Income |
$-20.74M |
$-20.74M |
|
$-20.74M |
|
$-20.74M |
|
$-20.74M |
|
$-21.15M |
|
$-21.08M |
|
63.22M |
|
63.22M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$133.09M |
|
-- |
|
$0.54M |
|
$133.63M |
|
$29.23M |
|
$16.92M |
|
$16.92M |
|
$46.15M |
|
$87.48M |
|
$87.48M |
|
$87.48M |
|
72.23M |
|
| Cash Flow Statement Financials | |
$-24.13M |
|
$-13.81M |
|
$35.74M |
|
$54.22M |
|
$52.03M |
|
$-2.19M |
|
$2.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.55 |
|
-- |
|
-- |
|
0.16 |
|
0.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.13M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-23.71% |
|
-23.71% |
|
-15.52% |
|
-19.86% |
|
$1.21 |
|
$-0.38 |
|
$-0.38 |
|